Efficacy, Safety, and Cost-Effectiveness Analysis of Ceftazidime-Avibactam versus Polymyxin B in the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections: A Target Trial Emulation DOI Creative Commons
Na Hu,

Fengjiao Xiao,

Yechao Chen

et al.

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: May 17, 2025

Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited, with polymyxin B (PMB) and ceftazidime-avibactam (CZA) being among the available choices. However, research on these is scarce significantly heterogeneous. This study aims to analyze efficacy, safety, cost-effectiveness of PMB CZA within a standardized target trial emulation (TTE) framework. retrospective emulated evaluate versus treating CRE infections. Conducted at Nanjing Drum Tower Hospital, this included adult patients treated or from July 2020 December 2022. Data demographics, treatment outcomes, costs were collected. The primary outcomes clinical cure, incidence adverse drug reactions (ADRs), cost-effectiveness. Secondary assessed 28-day all-cause mortality, microbiological eradication rates, acute kidney injury (AKI), gastrointestinal events. using modified intention-to-treat (mITT) effects, per-protocol propensity score overlap weighting (PSOW) methods. Between 1, 2020, 31, 2022, 492 hospitalized screened Hospital. Following inclusion exclusion criteria, 176 in mITT analysis, 153 analysis. cure rate was higher group compared across all analyses. mortality similar between groups, while microbial ADRs consistent but AKI occurred more frequently patients, events common group. strategy demonstrated 28.1% increase an incremental ratio 71,651.76 yuan. Sensitivity analyses confirmed robustness findings. demonstrates that has standard TTE overall two treatments. Pharmacoeconomic analysis also indicated cost-effective. https://www.chictr.org.cn ; identifier, ChiCTR2300067946.

Language: Английский

Efficacy, Safety, and Cost-Effectiveness Analysis of Ceftazidime-Avibactam versus Polymyxin B in the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections: A Target Trial Emulation DOI Creative Commons
Na Hu,

Fengjiao Xiao,

Yechao Chen

et al.

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: May 17, 2025

Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited, with polymyxin B (PMB) and ceftazidime-avibactam (CZA) being among the available choices. However, research on these is scarce significantly heterogeneous. This study aims to analyze efficacy, safety, cost-effectiveness of PMB CZA within a standardized target trial emulation (TTE) framework. retrospective emulated evaluate versus treating CRE infections. Conducted at Nanjing Drum Tower Hospital, this included adult patients treated or from July 2020 December 2022. Data demographics, treatment outcomes, costs were collected. The primary outcomes clinical cure, incidence adverse drug reactions (ADRs), cost-effectiveness. Secondary assessed 28-day all-cause mortality, microbiological eradication rates, acute kidney injury (AKI), gastrointestinal events. using modified intention-to-treat (mITT) effects, per-protocol propensity score overlap weighting (PSOW) methods. Between 1, 2020, 31, 2022, 492 hospitalized screened Hospital. Following inclusion exclusion criteria, 176 in mITT analysis, 153 analysis. cure rate was higher group compared across all analyses. mortality similar between groups, while microbial ADRs consistent but AKI occurred more frequently patients, events common group. strategy demonstrated 28.1% increase an incremental ratio 71,651.76 yuan. Sensitivity analyses confirmed robustness findings. demonstrates that has standard TTE overall two treatments. Pharmacoeconomic analysis also indicated cost-effective. https://www.chictr.org.cn ; identifier, ChiCTR2300067946.

Language: Английский

Citations

0